The Technical AnalystExchange: ASX Industry: Health Care Equipment & Services
Polynovo Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.98% $2.09
America/New_York / 3 mai 2024 @ 01:46
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 442.59 mill |
| EPS: | -0.0100 |
| P/E: | -209.00 |
| Earnings Date: | Feb 27, 2024 |
| SharesOutstanding: | 690.23 mill |
| Avg Daily Volume: | 1.710 mill |
| RATING 2024-05-02 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -209.00 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.86x |
| Company: PE -209.00 | industry: PE 54.21 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.364 (-165.27%) $-3.45 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.00 - 2.18 ( +/- 4.21%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.09 (3.98% ) |
| Volume | 0.514 mill |
| Avg. Vol. | 1.710 mill |
| % of Avg. Vol | 30.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PNV.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PNV.AX
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.